Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson’s latest earnings bested Wall Street estimates, as the company braces for one of its top-selling medicines ...
‘Back the blue?’: Wall Street Journal drags Trump over Jan. 6 pardons
The Wall Street Journal editorial board tore into President Donald Trump for pardoning the rioters who attacked the Capitol ...
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade
What Hartford Funds and Ned Davis Research found was that income stocks more than doubled the average annual return of ...
Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
Wall Street Lunch: AI Project Stargate A Go
Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...
J&J Tops Quarterly Profit Estimates on Cancer Drug Sales
Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...
Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...
Biden had no idea he signed natural gas export pause, Johnson says
La., recalled a meeting with President Biden from early last year during which the president appeared to forget he signed a ...
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...